{Reference Type}: Journal Article
{Title}: Association of Genomic Prostate Score at positive margin with recurrence after radical prostatectomy.
{Author}: Nourmohammadi Abadchi S;Salles DC;Flannery C;Sama V;Baehner FL;Zambon JP;Mendes AA;DePaula Oliveira L;Han M;Jing Y;Partin AW;Trock BJ;Lotan TL;
{Journal}: BJU Int
{Volume}: 0
{Issue}: 0
{Year}: 2024 Jul 2
{Factor}: 5.969
{DOI}: 10.1111/bju.16445
{Abstract}: <B>OBJECTIVE: </B>To evaluate the utility of the 17-gene Genomic Prostate Score® (GPS; MDxHealth, Irvine, CA, USA) performed on prostate cancer at the positive margin of the radical prostatectomy (RP) for its association with risk of subsequent biochemical recurrence (BCR).<BR><B>METHODS: </B>We designed a case-cohort for the outcome of BCR, selecting 223 from a cohort of 813 RP patients treated at Johns Hopkins from 2008 to 2017 with positive margins and available clinical data; of these, 213 had available tissue and clinical data. RNA was isolated from formalin-fixed paraffin-embedded tumour tissue adjacent to the positive surgical margin and the GPS was evaluable in 203 of these patients with a score ranging from 0 to 100, with higher scores indicating higher risk. All patients underwent RP with or without adjuvant radiation therapy (ART). The statistical analysis employed Cox proportional hazards regression models for outcome of BCR weighted for case-cohort design.<BR><B>RESULTS: </B>In univariable analysis, every 20-unit increase in the GPS was associated with a nearly threefold increase in risk of BCR (hazard ratio [HR] per 20 units 2.82, P < 0.001). In a multivariable Cox model adjusted for age, race, Cancer of the Prostate Risk Assessment Postsurgical score, Grade Group at the positive margin, and ART, the GPS was significantly associated with BCR (HR 1.56 per 20 units; 95% confidence interval 1.11-2.19; P = 0.011). The study is limited by its retrospective and single institution design.<BR><B>CONCLUSIONS: </B>The GPS at the positive surgical margin could help stratify prognosis and inform clinical decision-making regarding adjuvant therapy after RP.